免疫检查点抑制剂对耐药结直肠癌的研究现状  

Current status of immune checkpoint inhibitors in drug-resistant colorectal cancer

作　　者：袁沁 吴宏磊 徐可 殷佩浩 YUAN Qin;WU Hong-lei;XU Ke;YIN Pei-hao(School of Medicine and Life Sciences,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,Sichuan Province,China;Department of General Surgery,Putuo District Central Hospital of Shanghai y Shanghai 200062,China;Interventional Cancer Institute of Chiriese Integrative Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200062,China)

机构地区：[1]成都中医药大学医学与生命科学学院,四川成都611137 [2]上海市普陀区中心医院普外科,上海200062 [3]上海中医药大学中西医结合肿瘤介入研究所,上海200062

出　　处：《中国临床药理学杂志》2021年第2期183-185,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金面上基金资助项目(81873137);上海市进一步加快中医药事业发展三年行动计划(2018年-2020年)人才类基金资助项目(ZY(2018-2020)-RCPY-2016)。

摘　　要：错配修复缺陷(dMMR)/微卫星高频不稳定(MSI-H)结直肠癌因其致癌机制引起程序性细胞死亡蛋白1(PD-1)/程序性细胞死亡配体1(PD-L1)上调,对5-氟尿嘧啶(5-FU)等为基础的化疗方案产生肿瘤免疫性抵抗,出现耐药性。本文从以下几方面进行综述:dMMR/MSI-H结直肠癌耐药的特点和PD-1/PD-L1抑制剂在肿瘤中的生物学功能以及关于PD-1/PD-L1抑制剂单一治疗、联合其他治疗等治疗方法在耐药dMMR/MSI-H CRC治疗中的研究进展,为以后相关的临床研究提供新的想法。Mismatch repair defects(dMMR)/microsatellite high-frequency instability(MSI-H)in colorectal cancer cause upregulation of programmed cell death 1(PD-1)/programmed cell death ligand 1(PD-L1)due to its carcinogenic mechanism,resulting in tumor-immune resistance and drug resistance to 5-fluorouracil(5-Fu)and other chemotherapy regimens.This paper summarized the following aspects:the characteristics of drug resistance of dMMR/MSI-H colorectal cancer,the biological function of PD-1/PD-L1 inhibitors in tumors,and the research progress of single therapy of PD-1/PD-L1 inhibitors and other treatment methods in the treatment of drug-resistant dMMR/MSI-H CRC,so as to provide new ideas for related clinical studies in the future.

关 键 词：错配修复缺陷/微卫星不稳定性高结直肠癌 程序性细胞死亡1/程序性细胞死亡配体1 抑制剂 耐药 

分 类 号：R97[医药卫生—药品]